平行支架全腔内修复累及主动脉弓病变的长期结果
该单中心回顾性研究纳入33例累及主动脉弓病变患者,评估平行支架联合胸主动脉腔内修复(PG-TEVAR)的长期形态学与临床结局。结果显示I型内漏发生率高,60个月免于再干预率68%,需长期密切影像监测。
要点
- PG-TEVAR术后内漏发生率高,沟槽相关内漏可能被低估。
- 60个月免于总体PG-TEVAR相关再干预率为68%。
- 术后需频繁影像学监测以发现内漏和囊体扩张。
核心结论
- PG-TEVAR治疗累及主动脉弓病变导致高I型内漏率和长期再干预需求。
- 沟槽相关内漏可能比报道更常见,不应低估,因其可导致囊体扩张和再干预。
研究设计与样本
- 单中心回顾性分析2010年11月至2018年4月接受PG-TEVAR的患者。
- 排除既往或同期开放胸部或颈部去分支手术或弓部修复者。
- 共33例患者,其中女性8例,中位年龄74岁(IQR 67-79岁)。
主要发现
- 围手术期卒中率和30天死亡率分别为6%和9%。
- 术后直接CT显示27例患者共28个内漏(沟槽相关Ia型12个,沟槽相关Ib型9个,Ia型2个,Ic型2个,III型1个,未确定2个)。
- 技术和临床成功率分别为37%和30%。
- 总体PG-TEVAR相关再干预率为33%(n=11),60个月免于再干预率估计为68%。
- PG-TEVAR相关死亡率和全因死亡率分别为18%和34%。
关键数值与推荐
- 主要终点为免于总体PG-TEVAR相关再干预。
- 次要终点包括平行支架密封区失败(沟槽相关I型或Ic型内漏)、PG失败(闭塞或再干预)、卒中以及30天和总体PG-TEVAR相关和全因死亡率。
- 早期和总体PG密封区失败率分别为73%和36%,PG失败率分别为9%和18%。
临床怎么用
- PG-TEVAR可用于累及主动脉弓病变的全腔内修复,但需认识到高I型内漏和再干预风险。
- 术后应进行频繁影像学监测以早期发现内漏和囊体扩张。
局限性
- 单中心回顾性研究,样本量较小(33例)。
- 需要进一步研究比较PG-TEVAR与其他全腔内替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluated the long-term morphologic and clinical outcomes after thoracic endovascular aortic repair combined with parallel grafts (PG-TEVAR) for arch-involving aortic pathologies. METHODS: We performed a retrospective analysis of perioperative and follow-up data of patients who had undergone PG-TEVAR at a single vascular surgery center from November 2010 to April 2018. Patients with prior or simultaneous open chest or cervical debranching procedures or arch repair were excluded. The primary endpoint was freedom from overall PG-TEVAR-related reintervention. The secondary endpoints were parallel graft sealing zone failure (presence of gutter-related type I or Ic endoleak), PG failure (occlusion or reintervention), stroke, and 30-day and overall PG-TEVAR-related and all-cause mortality. Kaplan-Meier curves were used to estimate the freedom from reintervention and survival. Receiver operating characteristics curves were used to find the optimal cutoff to prevent type Ia endoleak-related reintervention. RESULTS: A total of 33 patients, including 8 women, with a median age of 74 years (interquartile range, 67-79 years) had undergone PG-TEVAR (chimney, periscope, and sandwich in 20, 15, and 13 patients, respectively) with proximal landing in Ishimaru zone 0, 1, or 2 in 4, 5, and 24 patients, respectively. The aortic pathologies included type B aortic dissection (acute and chronic, eight and six, respectively), degenerative aneurysm (n = 10), type Ia endoleak (n = 3), para-anastomotic/patch aneurysm (n = 4), left subclavian artery aneurysm (n = 1), and traumatic rupture (n = 1). The perioperative stroke rate and 30-day mortality was 6% and 9%, respectively. Direct postoperative computed tomography revealed 28 endoleaks (gutter-related type Ia, 12; gutter-related type Ib, 9; type Ia, 2; type Ic, 2; type III, 1; undetermined, 2) in 27 patients. The technical and clinical success rate was 37% and 30%, respectively. The mean follow-up for survival was 48 ± 31 months. The latest radiologic follow-up demonstrated 12 remaining and 1 new endoleak. The early and overall PG sealing zone failure and PG failure was 73% and 36% and 9% and 18%, respectively. The overall PG-TEVAR-related reintervention rate was 33% (n = 11). The estimated freedom from overall PG-TEVAR-related reintervention was 68% at 60 months. The main graft oversizing and length oversizing rates were not significantly associated statistically with the type Ia endoleak-related reintervention rate. The PG-TEVAR-related and all-cause mortality were 18% and 34%, respectively. CONCLUSIONS: PG-TEVAR for total endovascular repair of arch-involving aortic pathologies resulted in a high rate of type I endoleaks and the need for long-term reintervention. Gutter-related endoleaks might be more frequent than reported and should not be underestimated because they can lead to sac enlargement and reintervention. Frequent radiologic surveillance is mandatory. Further studies comparing PG-TEVAR to other total endovascular alternatives are required to confirm these findings.
引用
- Dueppers P, Reutersberg B, Rancic Z, et al. Long-term results of total endovascular repair of arch-involving aortic pathologies using parallel grafts for supra-aortic debranching. J Vasc Surg. 2021. PMID: 34606961. doi:10.1016/j.jvs.2021.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。